Nestlé Health Science further invests in Aimmune TherapeuticsNestlé Health Science further invests in Aimmune Therapeutics Up to 250 million people globally are estimated to suffer from food allergies, between 5-8% of children and 1-2% of adults.Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach to treating life-threatening food allergies is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. Aimmune media contact: Lauren Barbiero, (646) 564-2156, Julie Normant, The following content is restricted for healthcare professional only. Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides … Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health ScienceAimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to The FDA approved Palforzia on Jan. 31 for children between the ages of 4 and 17 with a confirmed peanut allergy. Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and advice to Aimmune through the pipeline forum and in addition has a three-month exclusive right of first negotiation for any development program in the event Aimmune considers licensing or partnering such a program. Nestlé Health Science purchased 3,237,529 newly issued shares of Aimmune… Sorry, you need to enable JavaScript to visit this website. In addition, this capital will help fund the continued advancement of our pipeline.” Investing in food allergy therapies is a natural extension of NHSc’s current pediatric food allergy portfolio which includes its products for babies and young children with Cow’s Milk Protein Allergy (Althéra, Alfaré and Alfamino) and its investment in Before Brands, which makes SpoonfulOne, a nutrition-based, early childhood, food allergy-prevention product. Recent News. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced the closing of the $145 million equity investment by Nestlé Health Science. Nestlé Health Science further invests in Aimmune Therapeutics BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 5, 2020-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé … Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a globally recognized leader in the field of nutritional science.
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. LEARN MORE ABOUT AIMMUNE. Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. investigation and that has not yet been approved for marketing by the Support Regulatory Filings and Market Understanding — We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of Good food, good life – that is what we stand for. February 05, 2020. For more information, please see visit: The following content is restricted for healthcare professional only. Aimmune Therapeutics to Present at the 2020 … This press release concerns a product that is under clinical About Aimmune Therapeutics and AR101 LEARN MORE ABOUT AIMMUNE. Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies. The powder is mixed into semi-solid food for the patient to then ingest. Everything you need to know about Nestlé is here: brands, key figures, milestones.Nestlé touches the lives of billions of people every day: the farmers who grow our ingredients, our consumers, and the communities where we live and work.Learn about Nestlé’s brands and what we’re doing to make our products tastier and healthier.Innovation is at the heart of Nestlé. “We first invested in Aimmune in 2016 and have been closely involved since then,” said Greg Behar, NHSc CEO and Aimmune Therapeutics Board Member. You will be redirected. Sorry, you need to enable JavaScript to visit this website. A downside of Palforzi… The treatment, a powder containing the peanut allergen, seeks to gradually desensitize the individual to small amounts of peanuts that may be hidden in food. We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimizing treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.” The strategic investment launches a two-year strategic collaboration between Nestlé Health Science and Aimmune, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum. Additional details regarding the equity investment and strategic
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. LEARN MORE ABOUT AIMMUNE. Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. investigation and that has not yet been approved for marketing by the Support Regulatory Filings and Market Understanding — We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of Good food, good life – that is what we stand for. February 05, 2020. For more information, please see visit: The following content is restricted for healthcare professional only. Aimmune Therapeutics to Present at the 2020 … This press release concerns a product that is under clinical About Aimmune Therapeutics and AR101 LEARN MORE ABOUT AIMMUNE. Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies. The powder is mixed into semi-solid food for the patient to then ingest. Everything you need to know about Nestlé is here: brands, key figures, milestones.Nestlé touches the lives of billions of people every day: the farmers who grow our ingredients, our consumers, and the communities where we live and work.Learn about Nestlé’s brands and what we’re doing to make our products tastier and healthier.Innovation is at the heart of Nestlé. “We first invested in Aimmune in 2016 and have been closely involved since then,” said Greg Behar, NHSc CEO and Aimmune Therapeutics Board Member. You will be redirected. Sorry, you need to enable JavaScript to visit this website. A downside of Palforzi… The treatment, a powder containing the peanut allergen, seeks to gradually desensitize the individual to small amounts of peanuts that may be hidden in food. We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimizing treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.” The strategic investment launches a two-year strategic collaboration between Nestlé Health Science and Aimmune, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum. Additional details regarding the equity investment and strategic